Dr Bradley Corr discusses what he’s most excited to hear at the SGO Annual Meeting, including new data on antibody-drug ...

A small carefully constructed and blinded clinical trial confirms that percutaneous intervention significantly relieves angina in patients with chronic total obstruction.

Doctors are told to raise safety concerns, but some face isolation, disciplinary action, and lasting career consequences when ...

Phase 1 data suggest that WVE-007, an investigational siRNA drug given by injection, leads to reductions in visceral fat, waist circumference, and body weight.

ND4 variant (m.11232T>C) to severe neurologic injury after sevoflurane in patients with Venezuelan maternal ancestry, prompting international alerts.

Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.

New federal dietary guidance includes advice on boosting testosterone levels, which clinicians say is only partially rooted in evidence.

Because of fear of allergic reactions, some patients need psychological counseling and dietary support for a more positive attitude toward food.

European regulators recommended a subcutaneous formulation for a key anti-CD38 therapy, offering clinicians and patients more flexible administration options for multiple myeloma.

High doses of erythropoiesis-stimulating agents were associated with an increased risk for cancer in patients on dialysis, but the real risk attributed to these medications remains unclear.

Medications for alcohol use disorder are associated with reduced alcohol-related healthcare utilization and cost savings in real-world settings.

EMA’s panel backs a targeted therapy, which reduces lymphadenopathy and restores B-cell populations in patients with activated phosphoinositide 3-kinase delta syndrome.